|  Help  |  About  |  Contact Us

Publication : AIMP1 deficiency enhances airway hyperreactivity in mice via increased TH2 immune responses.

First Author  Hong HJ Year  2012
Journal  Clin Immunol Volume  143
Issue  3 Pages  256-65
PubMed ID  22472603 Mgi Jnum  J:184868
Mgi Id  MGI:5426487 Doi  10.1016/j.clim.2012.02.004
Citation  Hong HJ, et al. (2012) AIMP1 deficiency enhances airway hyperreactivity in mice via increased T(H)2 immune responses. Clin Immunol 143(3):256-65
abstractText  Aminoacyl tRNA synthetase complex-interacting multicomplex protein 1 (AIMP1) is known as a novel cytokine carrying out a variety of biological activities, including angiogenesis and wound repair. In our previous reports AIMP1 was demonstrated to induce T(H)1 polarization. However, the effects of AIMP1 deficiency in T(H)1 or T(H)2 immune disorders remain unclear. In this study, we characterized phenotypes of AIMP1-deficient mice and investigated the role of AIMP1 in T(H)2-biased airway hyperreactivity. Clinical signs of allergic airway inflammation were assessed in AIMP1-deficient mice and the effects of AIMP1 deficiency on production of T(H)2 cytokines were evaluated in T cells using AIMP1-specific siRNA. Additionally, the enhanced pause values and histologic analysis were assessed in mice receiving AIMP1-deficient CD4(+) T cells with OVA challenge. Clinical signs of spontaneous airway inflammation were noted in AIMP1-deficienct mice. AIMP1-deficient mice showed strongly increased Penh values in response to methacholine without any allergen exposure. Adoptive transfer of AIMP1-deficient CD4(+) T cells to OVA-sensitized C57BL/6 mice exacerbated OVA-induced airway inflammation and increased infiltration of inflammatory cells into the lung. Furthermore, lung DCs in AIMP1-deficient mice showed increased expression of surface molecules, and IL-12p40 level in sera significantly decreased in AIMP1-deficient mice compared to that of wild type mice. These results strongly indicate that AIMP1 plays a role in negatively regulating T(H)2 responses in vivo, and AIMP1 can be employed as a novel therapeutic agent against T(H)2-biased diseases, particularly asthma.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

5 Authors

3 Bio Entities

0 Expression